PB1922: EFFECTIVENESS OF AZACITIDINE IN FRONTLINE HIGHER-RISK MYELODYSPLASTIC SYNDROME (HR MDS): A RETROSPECTIVE COHORT STUDY OF 382 PATIENTS. (23rd June 2022) - Rajakumaraswamy, N.; Gandhi, M.; Wei, A. H.; Sallman, D. A.; Daver, N. G.; Mo, S.; Iqbal, S.; Chen, M.; Wang, Y.; Vyas, P.